FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386725837> ?p ?o ?g. }

• W4386725837 abstract "There is little evidence of abiraterone acetate (AA) plus prednisone for patients with non-metastatic castration-resistant prostate cancer (nmCRPC). In this study, we conducted a comparative analysis of real-world survival outcomes between AA plus prednisone and enzalutamide (Enz) in patients with nmCRPC, utilizing our consortium dataset.The clinical records of 133 nmCRPC patients treated with first-line Enz or AA plus prednisone were analyzed. The primary endpoints of the study were overall survival (OS) and cancer-specific survival (CSS). Cumulative incidence function (CIF) using Fine and Gray models was also utilized to assess non-cancer-caused death considering the competing risk of cancer-caused death.During a median follow-up of 36 months, 34 patients (25.6%) had deceased, with a median OS of 99 months in the entire cohort. There were no significant differences in comorbidities between the Enz and AA groups. Time to PSA progression (TTPP: HR 0.81, 95% CI 0.51-1.30, P = 0.375) and CSS (HR 1.32, 95% CI 0.55-3.44, P = 0.5141) were comparable between the two groups. However, intriguingly, there was a trend towards shorter OS in patients treated with AA plus prednisone compared to Enz (HR 0.57, 95% CI 0.29-1.12, P = 0.0978, median of 99 and 69 months in Enz and AA groups, respectively). CIF analysis revealed that nmCRPC patients treated with AA plus prednisone were more likely to result in non-cancer-caused death than those treated with Enz (HR 5.22, 95% CI 1.88-14.50, P = 0.0014).Our real-world survival analysis suggests that while AA plus prednisone may demonstrate comparable treatment efficacy to Enz in the context of nmCRPC, there may be an increased risk of non-cancer-caused death. Physicians should take into consideration this information when making treatment decisions for patients with nmCRPC." @default.
• W4386725837 created "2023-09-15" @default.
• W4386725837 creator A5002217801 @default.
• W4386725837 creator A5003587912 @default.
• W4386725837 creator A5006776440 @default.
• W4386725837 creator A5007413510 @default.
• W4386725837 creator A5015650717 @default.
• W4386725837 creator A5021692335 @default.
• W4386725837 creator A5022320757 @default.
• W4386725837 creator A5024205770 @default.
• W4386725837 creator A5024298648 @default.
• W4386725837 creator A5029382212 @default.
• W4386725837 creator A5029568633 @default.
• W4386725837 creator A5030580122 @default.
• W4386725837 creator A5038102022 @default.
• W4386725837 creator A5039665271 @default.
• W4386725837 creator A5040122887 @default.
• W4386725837 creator A5045104199 @default.
• W4386725837 creator A5058151593 @default.
• W4386725837 creator A5062447398 @default.
• W4386725837 creator A5064534893 @default.
• W4386725837 creator A5064917014 @default.
• W4386725837 creator A5065751906 @default.
• W4386725837 creator A5071012389 @default.
• W4386725837 creator A5071593174 @default.
• W4386725837 creator A5073538169 @default.
• W4386725837 creator A5075132299 @default.
• W4386725837 creator A5078064024 @default.
• W4386725837 creator A5081087358 @default.
• W4386725837 date "2023-09-14" @default.
• W4386725837 modified "2023-09-26" @default.
• W4386725837 title "<scp>Real‑world</scp> survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for <scp>nonmetastatic castration‐resistant</scp> prostate cancer" @default.
• W4386725837 cites W1919512980 @default.
• W4386725837 cites W2013602946 @default.
• W4386725837 cites W2015712245 @default.
• W4386725837 cites W2019607817 @default.
• W4386725837 cites W2098998490 @default.
• W4386725837 cites W2131170102 @default.
• W4386725837 cites W2150906637 @default.
• W4386725837 cites W2159810380 @default.
• W4386725837 cites W2167331614 @default.
• W4386725837 cites W2397464061 @default.
• W4386725837 cites W2605070587 @default.
• W4386725837 cites W2620798309 @default.
• W4386725837 cites W2792086148 @default.
• W4386725837 cites W2795789232 @default.
• W4386725837 cites W2810806599 @default.
• W4386725837 cites W2913767564 @default.
• W4386725837 cites W2954115616 @default.
• W4386725837 cites W2967692526 @default.
• W4386725837 cites W2976281902 @default.
• W4386725837 cites W2977591231 @default.
• W4386725837 cites W2984712394 @default.
• W4386725837 cites W3031020438 @default.
• W4386725837 cites W3131822249 @default.
• W4386725837 cites W3145952188 @default.
• W4386725837 cites W3200992038 @default.
• W4386725837 cites W4205497227 @default.
• W4386725837 cites W4211087830 @default.
• W4386725837 cites W4223454845 @default.
• W4386725837 doi "https://doi.org/10.1002/cam4.6536" @default.
• W4386725837 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37706578" @default.
• W4386725837 hasPublicationYear "2023" @default.
• W4386725837 type Work @default.
• W4386725837 citedByCount "0" @default.
• W4386725837 crossrefType "journal-article" @default.
• W4386725837 hasAuthorship W4386725837A5002217801 @default.
• W4386725837 hasAuthorship W4386725837A5003587912 @default.
• W4386725837 hasAuthorship W4386725837A5006776440 @default.
• W4386725837 hasAuthorship W4386725837A5007413510 @default.
• W4386725837 hasAuthorship W4386725837A5015650717 @default.
• W4386725837 hasAuthorship W4386725837A5021692335 @default.
• W4386725837 hasAuthorship W4386725837A5022320757 @default.
• W4386725837 hasAuthorship W4386725837A5024205770 @default.
• W4386725837 hasAuthorship W4386725837A5024298648 @default.
• W4386725837 hasAuthorship W4386725837A5029382212 @default.
• W4386725837 hasAuthorship W4386725837A5029568633 @default.
• W4386725837 hasAuthorship W4386725837A5030580122 @default.
• W4386725837 hasAuthorship W4386725837A5038102022 @default.
• W4386725837 hasAuthorship W4386725837A5039665271 @default.
• W4386725837 hasAuthorship W4386725837A5040122887 @default.
• W4386725837 hasAuthorship W4386725837A5045104199 @default.
• W4386725837 hasAuthorship W4386725837A5058151593 @default.
• W4386725837 hasAuthorship W4386725837A5062447398 @default.
• W4386725837 hasAuthorship W4386725837A5064534893 @default.
• W4386725837 hasAuthorship W4386725837A5064917014 @default.
• W4386725837 hasAuthorship W4386725837A5065751906 @default.
• W4386725837 hasAuthorship W4386725837A5071012389 @default.
• W4386725837 hasAuthorship W4386725837A5071593174 @default.
• W4386725837 hasAuthorship W4386725837A5073538169 @default.
• W4386725837 hasAuthorship W4386725837A5075132299 @default.
• W4386725837 hasAuthorship W4386725837A5078064024 @default.
• W4386725837 hasAuthorship W4386725837A5081087358 @default.
• W4386725837 hasBestOaLocation W43867258371 @default.
• W4386725837 hasConcept C120665830 @default.
• W4386725837 hasConcept C121332964 @default.
• W4386725837 hasConcept C121608353 @default.
• W4386725837 hasConcept C126322002 @default.
• W4386725837 hasConcept C126894567 @default.
• W4386725837 hasConcept C143998085 @default.

• next